VRAMEDIUM SIGNALFINANCIAL10-K

Vera Bradley shows material revenue contraction with reduced operating losses and significant inventory normalization in fiscal 2026.

The company appears to be managing through a challenging period with substantially lower sales, but has meaningfully reduced its cost structure and improved cash flow from operations. The significant inventory reduction suggests either better demand planning or continued weak sales requiring inventory liquidation.

Comparing 2026-03-27 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

Vera Bradley experienced broad-based financial contraction in fiscal 2026, with gross profit declining substantially alongside meaningful reductions in SG&A expenses. Despite the revenue pressures, the company improved its operating cash flow and reduced operating losses, while cutting capital expenditures significantly. The material reduction in inventory levels and overall current assets suggests aggressive cost management, though stockholders' equity declined meaningfully reflecting the challenging operating environment.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-68.3%
$10.4M→$3.3M

Capex reduced 68.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-39%
$30.4M→$18.5M

Cash declined 39% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Gross Profit
P&L
-33.1%
$186.8M→$125.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Interest Expense
P&L
-32.3%
$263K→$178K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Inventory
Balance Sheet
-31%
$110.0M→$76.0M

Inventory drawn down 31% — strong sell-through or deliberate destocking; watch for supply constraints.

SG&A Expense
P&L
-29.3%
$223.8M→$158.1M

SG&A reduced 29.3% — improved cost efficiency or headcount reduction improving operating margins.

Operating Cash Flow
Cash Flow
+29.3%
-$14.1M→-$10.0M

Operating cash flow grew 29.3% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
-27.4%
$164.9M→$119.7M

Current assets declined 27.4% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-26.4%
$179.0M→$131.6M

Equity decreased 26.4% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Income
P&L
+24.7%
-$42.4M→-$31.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-28
ADDED
The registrant ha d 27,965,338 s hares of its common stock outstanding as of March 20, 2026.
intends to file such proxy statement with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after its fiscal year ended January 31 , 2026 .
and its wholly-owned subsidiaries, including Vera Bradley Designs, Inc., except where the context requires otherwise or where otherwise indicated.
The fiscal years ending January 31, 2026 ( fiscal 2026 ) and February 1, 2025 ( fiscal 2025 ) were 52-week periods.
The fiscal year ending February 3, 2024 ( fiscal 2024 ) was a 53-week period .
+7 more — sign up free →
REMOVED
The registrant ha d 27,700,900 s hares of its common stock outstanding as of March 21, 2025.
intends to file such proxy statement with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after its fiscal year ended February 1, 2025.
References to Vera Bradley relate to the Vera Bradley stand-alone brand and references to Pura Vida relate to the Pura Vida stand-alone brand, except where the context requires otherwise or where otherwise indicated.
The fiscal year ending February 1, 2025 ( fiscal 2025 ) was a 52-week period.
The fiscal year ending February 3, 2024 ( fiscal 2024 ) was a 53-week period.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →